Abigail Liebow

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya et al. · The Lancet · 2013 · 574 citations

Life Sciences, Biochemistry, Pharmacology +16

siRNA Conjugates Carrying Sequentially Assembled Trivalent <i>N-</i>Acetylgalactosamine Linked Through Nucleosides Elicit Robust Gene Silencing <i>In Vivo</i> in Hepatocytes

Shigeo Matsuda, Kristofer Keiser, Jayaprakash K. Nair et al. · ACS Chemical Biology · 2015 · 213 citations

Pharmacy, Molecular Biology, Pharmacology +17

An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria

Abigail Liebow, Xingsheng Li, Timothy Racie et al. · Journal of the American Society of Nephrology · 2016 · 200 citations · Full text

Life Sciences, Biochemistry, Molecular Medicine +15

Hepatocyte‐Specific Delivery of siRNAs Conjugated to Novel Non‐nucleosidic Trivalent <i>N</i>‐Acetylgalactosamine Elicits Robust Gene Silencing in Vivo

Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Muthusamy Jayaraman et al. · ChemBioChem · 2015 · 184 citations

Pharmacy, Biotechnology, Molecular Biology +17

Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification

Amy Chan, Abigail Liebow, Makiko Yasuda et al. · Molecular Therapy — Nucleic Acids · 2015 · 128 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +16